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Abstract
Objective. Acute pancreatitis is one the important causes of systemic inflammatory response syndrome (SIRS). SIRS results
in gut barrier dysfunction that allows bacterial translocation and pancreatic infection to occur. Indomethacin has been used
to reduce inflammatory process and bacterial translocation in experimental models. The purpose of this study was to
determine the effect of inhibition of prostaglandin E2 (PGE2) production on pancreatic infection. Materials and methods. An
experimental model of severe acute pancreatitis (AP) was utilized. The animals were divided into three groups: sham
(surgical procedure without AP induction); pancreatitis (AP induction); and indomethacin (AP induction plus
administration of 3 mg/kg of indomethacin). Serum levels of interleukin (IL)-6 and IL-10, PGE2, and tumor necrosis
factor (TNF)-a were measured 2 h after the induction of AP. We analyzed the occurrence of pancreatic infection with
bacterial cultures performed 24 h after the induction of AP. The occurrence of pancreatic infection (considered positive
when the CFU/g was 105), pancreatic histologic analysis, and mortality rate were studied. Results. In spite of the
reduction of IL-6, IL-10, and PGE2 levels in the indomethacin group, TNF-a level, bacterial translocation, and pancreatic
infection were not influenced by administration of indomethacin. The inhibition of PGE2 production did not reduce
pancreatic infection, histologic score, or mortality rate. Conclusion. The inhibition of PGE2 production was not able to
reduce the occurrence of pancreatic infection and does not have any beneficial effect in this experimental model. Further
investigations will be necessary to discover a specific inhibitor that would make it possible to develop an anti-inflammatory
therapy.
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Introduction
It is known that acute severe pancreatitis (AP) is an
abdominal catastrophe and has a high mortality rate
[1]. At the present time, no specific therapy has been
shown to be uniformly effective in reducing morbidity
and mortality [1,2].
Severe AP is one of the most important causes of
systemic inflammatory response syndrome (SIRS)
[3]. After the initial injury to the pancreas acinar
cell a local inflammation of the pancreas is responsible
for triggering a sequence of events that ends in a
generalized inflammatory response that results in
multiple organ damage [4].
Knowledge about the pathophysiology of AP has
increased considerably in the past few years. However,
acute severe pancreatitis remains a harmful disease
with a high mortality rate. The systemic inflammatory
response is mediated by cytokines such as IL-1, IL-6,
IL-8, TNF-a, prostaglandin E2 (PGE2), platelet-
activating factor (PAF), and C-reactive protein [5].
There is now evidence that plasma levels of TNF-a,
IL-1, and IL-6 increase early in the course of AP and
they are correlated with the severity of the disease.
Furthermore, a high level of inflammatory mediators
is responsible for fuelling the SIRS [6].
SIRS results in several organ dysfunctions such as
respiratory distress, renal failure, homodynamic in-
stability, and gut barrier dysfunction. The gut barrier
dysfunction allows the occurrence of bacterial trans-
location. Mucosal barrier damage during AP leads to
an increase in permeability, which promotes the
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escape of bacteria from the gut [7]. Additionally, it has
been speculated that release of excessive amounts of
inflammatory mediators leads to failure of the intes-
tinal barrier [8]. Therefore, the occurrence of bacter-
ial translocation in AP can be considered an indirect
marker of systemic inflammatory response level.
Pancreatic infection is the most serious complica-
tion of severe AP, with a mortality rate up to 80%.
The pathogenesis of pancreatic infection in AP
remains poorly understood. Increased gut bacterial
translocation in AP has been demonstrated in a
number of previous studies, where bacterial translo-
cation has been correlated with pancreatic infection
[9,10]. Our group previously demonstrated the oc-
currence of bacterial translocation in experimental AP
[11,12].
PEG2 and prostaglandin-derived mediators play an
important role in mediating the systemic inflamma-
tory response. Cyclooxygenases (COX) are the key
enzymes of prostaglandin synthesis. Inhibition of
PEG2 production could reduce the systemic inflam-
matory response and therefore have some benefits in
AP [13,14].
Indomethacin is an unselective COX inhibitor
capable of reducing PEG2 production. In experimen-
tal models of shock and burn injury, administration of
PEG2 synthesis blocker prevented the occurrence of
bacterial translocation. It has been reported that
high levels of PEG2 are responsible for suppression
of splenic T-cell proliferation during sepsis resulting in
bacterial translocation [15]. However, the role of
reduction of PEG2 production in cytokine production
and pancreatic infection has not been evaluated in
experimental AP.
To elucidate the role of PEG2 in severe AP we
sought to analyze the effects of inhibition of PEG2
production on the local and systemic response in
experimental severe AP.
Materials and methods
Animals
One hundred twenty male Wistar rats, weighing 225
250 g, were housed in individual cages. The tempera-
ture was kept at 20228C, a 12 h light-dark cycle was
maintained, and all rats were fed with a standard rat
chow and water ad libitum during the entire protocol;
any fast period was observed. The experimental
protocol was approved by the University of Sa˜o Paulo
Ethics Commission. All animals received care in
accordance with ‘Guide for the Care and Use of
Laboratory Animals.’
Experimental design
Animals were divided into three experimental groups:
group I (sham group)  40 rats submitted to surgical
procedure without induction of AP plus intraperito-
neal administration of 0.5 ml of saline; group II
(pancreatitis group)  40 rats submitted to induction
of AP by sodium taurocholate injection into the
pancreatic duct plus intraperitoneal administration
of 0.5 ml of saline; and group III (indomethacin
group)  40 rats submitted to induction of AP by
sodium taurocholate injection into the pancreatic duct
plus intraperitoneal administration of 3 mg/kg of
indomethacin.
Induction of acute pancreatitis
The rats were operated under aseptic conditions,
using ketamine anesthesia 0.2 ml/100 g (Ketalar†).
The pancreas was exteriorized through a midline
abdominal incision, the proximal bile duct was
clamped at the liver hilum level, and the distal bile
duct was cannulated using a 19G polyethylene
catheter through the duodenal wall. AP was induced
by intraductal retrograde injection of 0.5 ml of 2.5%
sodium taurocholate (Sigma-Chemical CompanyTM,
St Louis, MO, USA), with pressure control. Injection
flow was 0.2 ml/min. In the sham group, sodium
taurocholate injection was omitted, but the surgical
procedure was identical to the other groups, including
bile duct cannulation.
Administration of indomethacin and saline
Intraperitoneal administration of 3 mg/kg of indome -
thacin (Sigma-Chemical CompanyTM) was performed
after the induction of AP and the same dose was
repeated each 12 h.
Intraperitoneal administration of 0.5 ml of saline
was performed after the induction of AP and was
repeated every 12 h in groups I and II.
The administration of indomethacin and saline was
carried out in aseptic conditions.
Levels of cytokines
Blood samples were collected 2 h after the induction
of AP by needle aspiration. Plasma levels of IL-6,
IL-10, PGE2, and TNF-a were determined by
ELISA using kits provided by the manufactur-
ing company (Biosource International CytoscreenTM)
and expressed in pg/ml.
After induction of AP a systemic inflammatory
response is initiated and inflammatory mediators can
be measured and predict the severity of inflammation.
Inflammatory mediators have a very short half-life
and the high levels are observed in the first hours of
systemic inflammatory response. In a previous pub-
lication the authors showed that 2 h is an adequate
time to measure the cytokine levels in this experi-
mental model [16].
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Cultures and measurement of pancreatic infection
At 24 h after induction of AP, 20 rats from each group
were submitted to a midline laparotomy incision
under anesthesia and tissue samples were harvested
from the pancreas, mesenteric lymph nodes, and liver.
All samples were weighed and homogenized and
aerobic cultures were made using blood agar plates
and MacConkey agar plates and expressed in colony
forming units (CFU) per gram. Blood and free
peritoneal fluid were sampled using sterile syringes
and cultured using an automated culture system
(BACTEC PEDS Plus); all positive culture were
inoculated on blood agar plates and MacConkey
agar plates for bacterial identification.
The presence of pancreatic infection was accepted
when CFU/g was 105.
Histological analysis
Fragments of pancreas were harvested and fixed in
10% formaldehyde solution, embedded in paraffin,
sectioned, and stained with hematoxylin and eosin
(H&E) for light microscopy. The inflammatory
changes in the pancreas were analyzed and classified
by a previous described score [17].
Mortality study
Twenty animals from each group were kept alive for 7
days to determine the mortality rate. These animals
were maintained in individual cages, received regular
rat chow, and received saline solution or indometha-
cin according to the experimental protocol.
Statistical analysis
The data were analyzed using Graphpad Prism†
version 2.1. Different groups were compared using
Fisher’s exact test, ANOVA, Tukey, Mann-Whitney,
Kruskal-Wallis, and Dunn for the appropriate cate-
gorical data. Statistical analyses of the mortality rate
were performed using KaplanMeier curve and log-
rank test. Standard error was used and differences
were considered statistically significant when p values
were B0.05.
Results
All experiments were successfully concluded.
Cytokine levels
The levels of IL-6, IL-10, PGE2, and TNF-a were
undetectable in the sham group. A significantly higher
level of cytokines was observed in the pancreatitis
group. Significant decreases in levels of IL-6, IL-10,
and PGE2 were observed after indomethacin admin-
istration when compared with the pancreatitis group
(pB0.05). The administration of indomethacin was
not able to reduce the level of TNF-a (Table I).
Cultures
Pancreas. Positive cultures were not observed in the
sham group. A significantly increased rate of positive
bacterial cultures was obtained from pancreas cultures
in the pancreatitis and indomethacin groups. There
were no significant differences in the incidence of
positive cultures between these groups (Table II). A
high incidence of Escherichia coli was observed in
pancreas cultures in the pancreatitis and indometha-
cin groups.
Mesenteric lymph nodes. The pancreatitis and indo-
methacin groups had a significantly increased rate of
positive bacterial cultures when compared with the
sham group. Positive culture was not observed in the
sham group. There were no significant differences in
positive cultures and bacterial populations between
the pancreatitis and indomethacin groups (Table II).
Liver. A higher incidence of positive cultures was
observed in the pancreatitis and indomethacin
groups, without significant differences in both groups.
Positive culture was not observed in the sham group
(Table II).
Blood and peritoneal cavity. A significantly increased
rate of positive bacterial cultures was obtained from
blood and peritoneal cultures in the pancreatitis and
indomethacin groups in contrast with the sham group.
There was no significant difference between the
pancreatitis and indomethacin groups (Table II).
Pancreatic infection
Infection of pancreatic tissue was not observed in the
sham group. A high incidence of pancreatic infection
was observed in the pancreatitis group (60%) and was
also observed after indomethacin administration
(70%) (Figure 1).
Table I. Cytokine levels 2 h after AP induction in all analyzed
groups.
Group IL-6 IL-10 PGE2 TNF-a
Sham 0 0 1519115 0
Pancreatitis 184919 201934 672891360 175914
Indomethacin 7492* 47913* 306962* 155920
Mean value of plasma levels of IL-6, IL-10, PGE2, and TNF-a
expressed in pg/ml.
*pB0.05, indomethacin group vs pancreatitis group, ANOVA.
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Histologic analysis
Pancreatic edema, inflammatory infiltration, pancrea-
tic necrosis, pancreatic hemorrhage, and extrapan-
creatic fat necrosis were not reduced after
indomethacin administration (p0.05) (Figure 2).
Mortality study
Mortality was not observed in the sham group. Seven
rats died after induction of AP in the pancreatitis
group (35% mortality rate) and a significant reduction
of mortality rate was not observed in the indometha-
cin group (30% mortality rate) (Figure 3).
Discussion
PGE2 has an inflammatory property and its role in
AP is unclear. Several investigations have shown that
high levels of PGE2 could be responsible for trigger-
ing factors of inflammation and suggested that PGE2
inhibition could have beneficial effects in AP [14].
Furthermore, experimental studies in burn models
described the effects of PGE2 in bacterial transloca-
tion, proposing a suppression of intestinal T-cell
proliferation allowing bacterial translocation caused
by high levels of PGE2 [15,18].
All major inflammatory mediators have been stu-
died in recent years and researchers are still looking
for the elucidation of the key mediators in severe AP
associated with the discovery of specific inhibitors that
would make it possible to develop a clinically effective
anti-inflammatory therapy [19,20]. Trying to answer
this question and clarify the role of PGE2 in AP, we
used indomethacin as a PGE2 synthesis blocker and
correlated with other inflammatory mediators, such as
IL-6, IL-10, and TNF-a.
In the present study, the administration of indo-
methacin successfully inhibited PGE2 production and
also decreased levels of IL-6 and IL-10. However, it
was not able to reduce TNF-a levels. After adminis-
tration of indomethacin the levels of TNF-a were kept
high in the indomethacin group, demonstrating that
indomethacin was incapable of interfering with TNF-
a production. Reduction of PGE2 to very low levels in
this experimental protocol did not reduce the severity
of AP, the incidence of bacterial translocation and
pancreatic infection, or the mortality rate.
These data suggest that AP is a very complex
inflammatory process involving multiple mediators
and that PGE2 does not play a fundamental role in
this disease. With respect to the decreased serum
levels of IL-6 and IL-10, these data also suggest that
isolated reduction of IL-6 and IL-10 was not able to
influence the systemic inflammatory response in AP
and indicate that TNF-a might play a very important
role in the inflammatory process of severe AP and
might be a better marker of severity than other
inflammatory mediators [2124].
In septic burn models, high levels of PGE2 had
been correlated with macrophage dysfunction and
the administration of a COX inhibitor improved
Table II. Occurrence of bacterial translocation 24 h after taurocholate-induced pancreatitis.
Group Pancreas Mesenteric lymph nodes Liver Blood Peritoneal cavity
Sham 0/10* 0/10* 0/10* 0/10* 0/10*
Pancreatitis 8/10 8/10 4/10 7/10 8/10
Indomethacin 7/10 6/10 5/10 8/10 8/10
The occurrence of bacterial translocation was considered positive in all positive cultures.
*pB0.05, sham group vs pancreatitis and indomethacin groups, Fischer test.
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Figure 1. Percentage of pancreatic infections in rats with taurocho-
late-induced pancreatitis 24 h after induction of pancreatitis. *pB
0.05, sham group vs pancreatitis and indomethacin groups, Fischer
test.
0
5
10
15
H
is
to
lo
gi
c 
sc
or
e
*
Sham Pancreatitis Indomethacin
Figure 2. Histologic grading of lesions in histological analysis of
pancreatic tissue of rats with taurocholate-induced acute pancrea-
titis. *pB0.05, sham group vs pancreatitis and indomethacin
groups, Kruskal-Wallis test.
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immunity and reduced bacterial translocation [15].
Our study did not show any reduction in bacterial
translocation and pancreatic infection after indo-
methacin administration and marked PGE2 inhibi-
tion, suggesting that bacterial translocation in AP may
have a different and more complex mechanism than
those observed in septic-burn models.
The pancreatic infection was identified as the main
determinant of morbidity and mortality in severe AP
[25,26]. In necrotic pancreatic tissue, bacteria find
ideal conditions to replicate and form a secondary
infectious focus, which could fuel SIRS and increase
the mortality rate [27]. The present study indicates
that pancreatic infection is related to bacterial trans-
location when associated with AP.
Bacterial translocation is related to mucosal damage
caused by hemodynamic and microvascular dysfunc-
tion, intravascular thrombosis, vasodilatation, hypo-
tension, and endothelial damage triggered by TNF-a
[28]. Our present data show high and similar levels of
TNF-a in both groups that underwent induction of
AP. Based on these data, it is possible to speculate that
the intensity of the inflammatory process is mainly
related to TNF-a level and this can explain the high
occurrence of pancreatic infection and mortality rate
in this experimental model [20,22].
It has been reported that PGE2 increases vaso-
permeability and sequestration of inflammatory cells
[29,30]. However, in this model the reduction of
PGE2 to very low levels was not able to change the
local inflammatory process based on pancreatic his-
tologic analysis. The multiplicity of factors involved in
the pathophysiology of AP could explain this finding.
Furthermore, the mortality rate in this experimental
rat model did not have any beneficial advantage in rats
treated with indomethacin. Indeed, it is possible to
hypothesize that PGE2 does not play a central role in
the physiopathology of AP and PGE2 probably is not
an important target for anti-inflammatory therapy in
severe AP.
In conclusion, the inhibition of PGE2 production,
even when associated with reduction of IL-6 and IL-
10 levels, did not have any beneficial effect in this
experimental model of AP. Further investigations will
be necessary to discover specific inhibitors that would
make it possible to develop clinically effective anti-
inflammatory therapy in severe AP.
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